CANF Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q3

150.00K

-23.47%

Estimates Revision

The market is revising No Change the revenue expectations for Can-Fite BioPharma Ltd. (CANF) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -59.04%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-59.04%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast CANF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CANF is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.265

Low

2.50

Averages

2.50

High

2.50

Current: 0.265

Low

2.50

Averages

2.50

High

2.50

H.C. Wainwright

initiated

$2.50

2025-11-04

Reason

H.C. Wainwright

Price Target

$2.50

2025-11-04

initiated

Reason

H.C. Wainwright assumed coverage of Can-Fite BioPharma with a Buy rating and $2.50 price target. The firm says the company has two late-stage oral selective A3 adenosine receptor agonists, that are being developed as therapies for psoriasis and liver cancer, respectively. It believes A3AR agonists are novel and can selectively target pathogenic cells.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-04-15

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-04-15

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-03-21

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-03-21

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-03-20

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-03-20

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-03-18

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-03-18

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-03-03

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-03-03

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Can Fite Biopharma Ltd (CANF.A) is -0.95, compared to its 5-year average forward P/E of -0.77. For a more detailed relative valuation and DCF analysis to assess Can Fite Biopharma Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.77

Current PE

-0.95

Overvalued PE

4.22

Undervalued PE

-5.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.22

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.83

Undervalued EV/EBITDA

-0.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

21.41

Current PS

157.84

Overvalued PS

53.81

Undervalued PS

-11.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CANF News & Events

Events Timeline

No data

News

1.0

11-26Globenewswire

Can-Fite BioPharma CEO to Present Drug Developments at NobleCon21 on December 3

6.0

11-18Benzinga

D. Boral Capital Reiterates Buy Rating on Can Fite Biofarma with $11 Price Target Intact

4.5

11-18TipRanks

Tuesday's Major Stock Market Highlights: Morning News Summary!

People Also Watch

Frequently Asked Questions

What is Can Fite Biopharma Ltd (CANF) stock price today?

The current price of CANF is 0.265 USD — it has decreased -6.36 % in the last trading day.

What is Can Fite Biopharma Ltd (CANF)'s business?

Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

What is the price predicton of CANF Stock?

What is Can Fite Biopharma Ltd (CANF)'s revenue for the last quarter?

Can Fite Biopharma Ltd revenue for the last quarter amounts to 155.00K USD, decreased -21.32 % YoY.

What is Can Fite Biopharma Ltd (CANF)'s earnings per share (EPS) for the last quarter?

Can Fite Biopharma Ltd. EPS for the last quarter amounts to -0.00 USD, decreased % YoY.

What changes have occurred in the market's expectations for Can Fite Biopharma Ltd (CANF)'s fundamentals?

How many employees does Can Fite Biopharma Ltd (CANF). have?

Can Fite Biopharma Ltd (CANF) has 5 emplpoyees as of December 16 2025.

What is Can Fite Biopharma Ltd (CANF) market cap?

Today CANF has the market capitalization of 4.52M USD.